ReviewFrontiers in immunology2025
Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Saikosaponin D Improves Diarrhea-Predominant Irritable Bowel Syndrome by Regulating the Brain-Gut Axis: Based on Changes in the Gut HMGB1-TLR4/NF-κB Pathway and Hypothalamic HPA Axis.Digestive diseases and sciences · 2026Article
- Review
- Investigation of the Effect of Akkermansia muciniphila Muc T (ATCC BAA-835) on TLR4/NF-Kappa B/NLRP2 Signaling Pathway and Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome in Rats.Probiotics and antimicrobial proteins · 2026Article
- Plant-Derived Foods and Medicines as Modulators of the Gut Microbiome: Molecular Interactions and Implications for Disease and Therapy.Molecules (Basel, Switzerland) · 2026Review
- Targeting the Human Gut Microbiota-Between Conventional Therapy and Precision Genetic Engineering.Nutrients · 2026Review
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Long-Term Risk of Parkinson's Disease Following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.Journal of clinical medicine · 2026Review
- Biotic therapies for irritable bowel syndrome: current interventions.Gastroenterology report · 2026Review
- Co-fermentation ofFrontiers in nutrition · 2026Article
- Frequency of FODMAP-rich products consumption and irritable bowel syndrome-like symptoms among amateur runners.Frontiers in nutrition · 2026Article
- Serum FGL2 is correlated with the severity and psychological status of diarrhea-predominant irritable bowel syndrome.Frontiers in medicine · 2026Article
- Probiotics in irritable bowel syndrome: strain-specific effects, diet, and biomarker timing.Frontiers in cellular and infection microbiology · 2026Article
- Gut microbiota modulation in gastrointestinal disorders: current evidence and therapeutic perspectives.Frontiers in cellular and infection microbiology · 2025Review
- Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities.Oncology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction, and its pathogenesis remains unclear. Dysbiosis of the gut microbiota is associated with IBS. The gut microbiota may modulate IBS symptoms via the epithelial barrier, mucosal immunity, microbial metabolites (e.g., short-chain fatty acids and bile acids), and gut-brain signaling. Currently, dietary approaches, probiotics, prebiotics, rifaximin, and fecal microbiota transplantation show variable benefit; effects are strain-/context-dependent and evidence certainty varies, with adverse-event reporting inconsistent. This narrative review takes a subtype-aware, mechanism-first perspective to summarize microbiota functions, symptom links, and intervention evidence with safety considerations. This review offers new perspectives and insights for precision treatment and microbiome research in IBS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.